Ferrous Bisglycinate
drugOn this page
Also known as Bisglycino-iron(ii) chelateFerrochelFerrous glycinateIron bis-glycinateIron bis-glycinate chelate
Summary
Ferrous Bisglycinate (CHEMBL4297753) is a phase-3 clinical-stage unknown; indicated across 1 condition including anemia.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Unknown
- Indications: 1 condition
- Clinical trials: 5
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4297753 |
| Name | Ferrous Bisglycinate |
| Type | Unknown |
| Max phase | 3 |
Also known as: Bisglycino-iron(ii) chelate, Ferrochel, Ferrous bisglycinate, Ferrous glycinate, Iron bis-glycinate, Iron bis-glycinate chelate, FERROUS BISGLYCINATE
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| anemia | 3 | MONDO:0002280 | EFO:0004272 |
Clinical trials
Total trials: 5.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 3 |
| PHASE4 | 1 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04017598 | PHASE4 | COMPLETED | Potential Harms of Untargeted Iron Supplementation in Cambodia Where Iron Deficiency is Not the Cause of Anemia |
| NCT03009578 | PHASE3 | COMPLETED | Iron Sucrose Versus Ferrous Bis-glycinate for Treatment of Iron Deficiency Anemia |
| NCT06014983 | Not specified | RECRUITING | Efficacy and Adverse Side Effects of Two Forms of Iron in Pregnancy |
| NCT04469010 | Not specified | COMPLETED | Efficacy Evaluation of 16 Weeks’ Dietary Supplementation With Iron Bis-glycinate Plus Vitamin C on Cognitive Function, Subjective Mood, Fatigue, Health and Well-being |
| NCT04477018 | Not specified | COMPLETED | 16 Weeks’ Dietary Supplementation With Iron and Iron + Vitamin C on Cerebral Blood Flow and Energy Expenditure in Women of Reproductive Age |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: anemia